[ad_1] CFOTO | Future Publishing | Getty Images As its Covid gains evaporate, Pfizer wants a chunk of the budding weight loss drug market. Analysts say upcoming data on Pfizer’s experimental obesity pill, danuglipron, will be crucial in determining how competitive the company can be against the space’s dominant players Eli Lilly and Novo Nordisk….
[ad_1] A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, on March 29, 2023. George Frey | Reuters Eli Lilly on Thursday said supply of its blockbuster diabetes drug Mounjaro has improved in the U.S. after months…
[ad_1] Moderna on Thursday posted a steep loss for the third quarter as the drugmaker recorded a large write-down due to unused doses of its Covid vaccine, its only marketable product. Moderna’s total revenue for the period topped Wall Street’s expectations, even amid plummeting demand for its shot. Its outlook for next year, however, came…
[ad_1] CFOTO | Future Publishing | Getty Images Pfizer on Tuesday reported a narrower than expected adjusted loss for the third quarter as the drugmaker recorded charges largely related to struggles for its Covid antiviral treatment Paxlovid and Covid vaccine. Pfizer said that it recorded a $5.6 billion charge for inventory write-offs in the third…
[ad_1] Novo Nordisk and Eli Lilly reign over the anti-obesity drug market, and don’t expect this duopoly to end soon, analysts say. But other companies — both big and small — are hoping to grab a piece of this lucrative market. In a research note, Piper Sandler analyst Yasmeen Rahimi said the firm is tracking…
[ad_1] Bristol Myers Squibb on Thursday reported quarterly adjusted earnings that topped expectations and posted revenue in line with estimates, even as sales of the company’s popular blood cancer drug Revlimid plummeted due to generic competition. Bristol Myers, one of the world’s largest pharmaceutical companies, raked in $10.96 billion in revenue for the third quarter,…
[ad_1] CFOTO | Future Publishing | Getty Images Pfizer on Thursday said its combination vaccine candidates targeting Covid and the flu will move to a final-stage trial in the coming months after showing positive initial results in an early to mid-stage study. That moves the pharmaceutical giant and its German partner BioNTech one step closer…
[ad_1] Merck headquarters in Rahway, New Jersey, on Tuesday, April 18, 2023. Christopher Occhicone | Bloomberg | Getty Images Merck on Thursday reported third-quarter revenue and adjusted earnings that topped expectations on strong sales of its blockbuster cancer drug Keytruda, HPV vaccine Gardasil and surprisingly, its Covid drug Lagevrio. The pharmaceutical giant also increased its…
[ad_1] A vaccine from GlaxoSmithKline showed the potential to protect adults ages 50 to 59 from respiratory syncytial virus in a late-stage clinical trial, the company said Wednesday. The initial trial results suggest that GSK’s shot, known as Arexvy, could help protect a wider population from RSV, a disease that causes thousands of hospitalizations and…
[ad_1] Paxlovid, Pfizer’s antiviral medication to treat the coronavirus disease, is displayed in this picture taken on Oct. 7, 2022. Wolfgang Rattay | Reuters Pfizer will price a five-day course of its Covid antiviral drug Paxlovid at $1,390 when the company starts to transition it to the commercial market later this year. A company spokesperson…
